IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome

Leukemia. 2016 Jan;30(1):253-7. doi: 10.1038/leu.2015.135. Epub 2015 Jun 12.

Authors

N Landberg¹, N Hansen¹, M Askmyr¹, H Ågerstam¹, C Lassen¹, M Rissler¹, H Hjorth-Hansen^{2

3}, S Mustjoki⁴, M Järås¹, J Richter⁵, T Fioretos¹

Affiliations

¹ Department of Clinical Genetics, Lund University, Lund, Sweden.
² Department of Hematology, St Olavs Hospital, Trondheim, Norway.
³ Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
⁴ Hematology Research Unit Helsinki, Department of Clinical Chemistry and Hematology, University of Helsinki and Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
⁵ Department of Hematology and Vascular Disorders, Skåne University Hospital, Lund, Sweden.

PMID: 26067823
DOI: 10.1038/leu.2015.135

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

ADP-ribosyl Cyclase 1 / analysis
Antigens, CD34 / analysis
Fusion Proteins, bcr-abl / analysis
Humans
Interleukin-1 Receptor Accessory Protein / analysis*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
Neoplastic Stem Cells / chemistry*
Protein-Tyrosine Kinases / antagonists & inhibitors
Treatment Outcome

Substances

Antigens, CD34
BCR-ABL1 fusion protein, human
IL1RAP protein, human
Interleukin-1 Receptor Accessory Protein
Protein-Tyrosine Kinases
Fusion Proteins, bcr-abl
ADP-ribosyl Cyclase 1